The retest date and the expiry date are not the same document
A retest date says that material should be re-examined before use. An expiry date says it should not be used. The trade uses the second word for the first concept.
Harriet Oduya
Page 2 of 10 of this archive, newest first.
Archive — page 2
192 piecesThe supplement trade found this drug class quickly, and the citations did not improve
The resistance-training and energy-deficit literature supports a higher protein intake. None of it was conducted in people taking an incretin.
The advice is mostly reasonable. The certainty is not earned.
The gap between a defensible recommendation and a confident one is where most of the harm in this subject lives.
SURMOUNT-OSA misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A design note on withdrawal trials, and why the run-in matters
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
STEP 2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
REWIND was built to answer the stopping question, and it did
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
Which results are findings and which are consequences of the weight loss
A substantial proportion of the abnormal results generated during rapid weight loss are consequences of the weight loss rather than findings about the person.
Randomised withdrawal is the cleanest design in this field and the least discussed
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
What the four services actually offer, test by test
We asked all four services what they can determine, on what timescale, at what price, and under what accreditation. The answers are printed in full.
Bone density during rapid weight loss: what is known, which is less than you would hope
The evidence base is one secondary analysis, several small studies and a large amount of extrapolation from bariatric surgery.
Independent analysis puts a QSC survodutide lot at 99.4%, against 95.9% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
Measuring more frequently generates more flags and not more information
What the pivotal programmes measured and how often, which is a more defensible template than most published monitoring schedules.
Independent analysis puts a BCH orforglipron lot at 97.2%, against 93.1% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
SURMOUNT-OSA misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The lowest effective dose is a real concept with almost no data behind it
What the labels permit, what clinicians do, and the size of the gap between them.
SURPASS-2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Who signed this, and what did they undertake by signing it
Accreditation is granted for a defined scope of methods. A laboratory can be properly accredited and the test on your certificate can sit outside it.
The badge economy, and what it is actually certifying
Every step between the laboratory report and the product page removes information, and the badge is the last step.
The supply gap as a clinical event
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.